相似文献
1
The iron story: red smoke and magnetism?
Nephrol News Issues. 2014 Feb;28(2):2-3.
2
Non-intravenous approaches to iron therapy in chronic kidney disease: will it improve the benefit-to-risk ratio?
Nephrol News Issues. 2014 Feb;28(2):12, 14-5.
3
Toxic effects of IV iron preparations in CKD patients.
Nephrol News Issues. 2014 Feb;28(2):4-5.
4
Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation.
Am J Med. 2012 Oct;125(10):951-2. doi: 10.1016/j.amjmed.2012.02.009. Epub 2012 Jul 13.
5
Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.
Am J Kidney Dis. 2013 Jun;61(6):992-1000. doi: 10.1053/j.ajkd.2012.10.027. Epub 2013 Jan 31.
6
Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients.
Adv Chronic Kidney Dis. 2019 Jul;26(4):292-297. doi: 10.1053/j.ackd.2019.05.001.
7
Clinical practice guidelines for assessment and management of iron deficiency.
Kidney Int Suppl. 2008 Aug(110):S7-S11. doi: 10.1038/ki.2008.269.
8
Current recommendations on iron therapy in anaemia of chronic renal failure.
J Assoc Physicians India. 2002 Oct;50:1295-302.
9
Lessons from NKF-DOQI: iron management.
Semin Nephrol. 2000 Jul;20(4):330-4.
10
Anemia management in chronic kidney disease: intravenous iron steps forward.
Am J Hematol. 2010 May;85(5):311-2. doi: 10.1002/ajh.21682.
Zotero 插件